Literature DB >> 24285400

Involvement of B3GALNT2 overexpression in the cell growth of breast cancer.

Taisuke Matsuo1, Masato Komatsu1, Tetsuro Yoshimaru1, Kazuma Kiyotani1, Yasuo Miyoshi2, Mitsunori Sasa3, Toyomasa Katagiri1.   

Abstract

A number of glycosyltransferases have been identified and biologically characterized in cancer cells, yet their exact pathophysiological functions are largely unknown. Here, we report the critical role of β1,3-N-acetylgalactosaminyltransferase II (B3GALNT2), which transfers N-acetylgalactosamine (GalNAc) in a β1,3 linkage to N-acetylglucosamine, in the growth of breast cancer cells. Comprehensive transcriptomics, quantitative PCR and northern blot analyses indicated this molecule to be exclusively upregulated in the majority of breast cancers. Knockdown of B3GALNT2 expression by small interfering RNA attenuated cell growth and induced apoptosis in breast cancer cells. Overexpression of B3GALNT2 in HEK293T cells prompted secretion of the gene product into the culture medium, suggesting that B3GALNT2 is potentially a secreted protein. Furthermore, we demonstrated that B3GALNT2 is N-glycosylated on both Asn-116 and Asn-174 and that this modification is necessary for its secretion in breast cancer cells. Our findings suggest that this molecule represents a promising candidate for the development of a novel therapeutic targeting drug and a potential diagnostic tumor marker for patients with breast cancer, especially TNBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24285400     DOI: 10.3892/ijo.2013.2187

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  The effects of vitamin B6 compounds on cell proliferation and melanogenesis in B16F10 melanoma cells.

Authors:  Taisuke Matsuo; Aki Fujiwara; Kazuhiro Nakamura; Yasuyuki Sadzuka
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

2.  Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens.

Authors:  Madoka Sakata-Matsuzawa; Kaori Denda-Nagai; Haruhiko Fujihira; Miki Noji; Katrin Beate Ishii-Schrade; Atsushi Matsuda; Atsushi Kuno; Misato Okazaki; Katsuya Nakai; Yoshiya Horimoto; Mitsue Saito; Tatsuro Irimura
Journal:  PLoS One       Date:  2021-05-11       Impact factor: 3.240

3.  Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes.

Authors:  Taisuke Matsuo; Le Tan Dat; Masato Komatsu; Tetsuro Yoshimaru; Kei Daizumoto; Saburo Sone; Yasuhiko Nishioka; Toyomasa Katagiri
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

4.  Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population.

Authors:  Huangfu Wu; Guisheng He; Tao Song; Yazhen Zhang; Xiuxiu Chen; Huamin Chen; Wei Xiong; Chuanwei Sun; Chaoyang Zhao; Yunjing Chen
Journal:  Mol Genet Genomic Med       Date:  2019-07-08       Impact factor: 2.183

5.  MOXD1 knockdown suppresses the proliferation and tumor growth of glioblastoma cells via ER stress-inducing apoptosis.

Authors:  Pengfei Shi; Jie Xu; Fanwei Xia; Yinggang Wang; Jie Ren; Ping Liang; Hongjuan Cui
Journal:  Cell Death Discov       Date:  2022-04-07

6.  Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer.

Authors:  Li Wang; Lei Yu; Jian Shi; Feng Li; Caiyu Zhang; Haotian Xu; Xiangzhe Yin; Lixia Wang; Shihua Lin; Anastasiia Litvinova; Yanyan Ping; Shangwei Ning; Hongying Zhao
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

7.  Increased B3GALNT2 in hepatocellular carcinoma promotes macrophage recruitment via reducing acetoacetate secretion and elevating MIF activity.

Authors:  Tianxiao Yang; Yilin Wang; Wenjuan Dai; Xixi Zheng; Jing Wang; Shushu Song; Lan Fang; Jiangfan Zhou; Weicheng Wu; Jianxin Gu
Journal:  J Hematol Oncol       Date:  2018-04-04       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.